RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ryvu Therapeutics Stock

Ryvu Therapeutics Liabilities 2024

Ryvu Therapeutics Liabilities

143.61 M PLN

Ticker

RVU.WA

ISIN

PLSELVT00013

WKN

A1JUH2

In 2024, Ryvu Therapeutics's total liabilities amounted to 143.61 M PLN, a 9.14% difference from the 131.59 M PLN total liabilities in the previous year.

Ryvu Therapeutics Aktienanalyse

What does Ryvu Therapeutics do?

Ryvu Therapeutics SA is a Polish biotechnology company specializing in the research and development of innovative therapies for various types of cancers. The company was founded in 2015 and is headquartered in Krakow. Ryvu Therapeutics SA has gained a good reputation since its establishment and has attracted numerous renowned investors and partners. The company's business model focuses on the research and development of drugs based on new molecular therapies that can inhibit the activity of specific proteins in cancer patients. The company's strategy is to develop a wide range of innovative therapies with different mechanisms of action to maximize the potential of helping cancer patients. Ryvu Therapeutics SA operates in three main areas: research and development, preclinical development, and clinical development. The company has a highly experienced team of scientists and researchers dedicated to developing new anti-cancer drugs. The research focus is on identifying new therapeutic targets and molecules or compounds that can inhibit the activity of these targets. After identifying promising molecules in the research phase, the company conducts extensive preclinical studies to assess the safety and efficacy of the drug candidates. Different models are used to test the effects of the new therapies in vitro and in vivo. Upon successful completion of the preclinical phase, the company moves on to clinical development, where the effectiveness and safety of the drugs are evaluated in clinical trials in humans. Phase I clinical trials are conducted to determine the tolerability and dosage of the drug candidates. Phase II and III trials investigate the efficacy and safety of the drug in a larger number of patients. Ryvu Therapeutics SA has several molecules and compounds in its portfolio that are currently in different stages of development. Some examples include SEL120, a potential new drug that inhibits the activity of the CDK8 protein, which plays a crucial role in the development of cancer. SEL120 is currently in Phase I clinical trials. SEL201 is another drug candidate that targets CDK8 and is still in the preclinical research phase. SEL110 is a small molecule that targets the BCL-XL protein and has the potential to be effective against multiple types of cancer. It is currently in the early phase of clinical development. In conclusion, Ryvu Therapeutics SA is an innovative biotech company specializing in the development of new cancer therapies. The company already has several promising drug candidates in its portfolio, targeting different therapeutic targets and currently in various stages of development. Ryvu Therapeutics SA shows great potential to play a significant role in the treatment of cancer. Ryvu Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Ryvu Therapeutics's Liabilities

Ryvu Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Ryvu Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Ryvu Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Ryvu Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Ryvu Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Ryvu Therapeutics stock

What is the level of liabilities of Ryvu Therapeutics this year?

Ryvu Therapeutics has a debt balance of 143.61 M PLN this year.

What were the liabilities of Ryvu Therapeutics compared to the previous year?

The liabilities of Ryvu Therapeutics have increased by 9.14% increased compared to the previous year.

What are the consequences of high debt for investors of Ryvu Therapeutics?

High liabilities can pose a risk for investors of Ryvu Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Ryvu Therapeutics?

Low liabilities mean that Ryvu Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Ryvu Therapeutics affect the company?

An increase in liabilities of Ryvu Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Ryvu Therapeutics affect the company?

A decrease in the liabilities of Ryvu Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Ryvu Therapeutics?

Some factors that can influence the liabilities of Ryvu Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Ryvu Therapeutics so important for investors?

The liabilities of Ryvu Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Ryvu Therapeutics take to modify the liabilities?

To change its liabilities, Ryvu Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Ryvu Therapeutics pay?

Over the past 12 months, Ryvu Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ryvu Therapeutics is expected to pay a dividend of 0 PLN.

What is the dividend yield of Ryvu Therapeutics?

The current dividend yield of Ryvu Therapeutics is .

When does Ryvu Therapeutics pay dividends?

Ryvu Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ryvu Therapeutics?

Ryvu Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Ryvu Therapeutics?

For the upcoming 12 months, dividends amounting to 0 PLN are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ryvu Therapeutics located?

Ryvu Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ryvu Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ryvu Therapeutics from 9/13/2024 amounting to 0 PLN, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Ryvu Therapeutics pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Ryvu Therapeutics in the year 2023?

In the year 2023, Ryvu Therapeutics distributed 0 PLN as dividends.

In which currency does Ryvu Therapeutics pay out the dividend?

The dividends of Ryvu Therapeutics are distributed in PLN.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Ryvu Therapeutics

Our stock analysis for Ryvu Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ryvu Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.